REMEGEN (09995) issues profit warning, with an expected net loss attributable to shareholders of approximately 1.47 billion yuan in 2024, a year-on-year decrease of around 3%.

RemeGen (09995) announced that it is expected to achieve operating income of approximately RMB 1.715 billion in 2024, an increase of about 58% compared to the previous year. It is also expected to incur a net loss attributable to the owners of the parent company of approximately RMB 1.47 billion in 2024, a decrease of about 3% compared to the previous year. The announcement stated that the company's new drug research and development pipeline continues to progress, with several innovative drugs in key trial stages. Research and development investment has increased, while sales revenue of Tabotuximab and Vedotin monoclonal antibodies has grown rapidly. The gross profit margin of products continues to increase, and the sales expense ratio has significantly decreased. Therefore, it is expected that the company's net loss in 2024 will decrease, showing a decreasing trend in losses, both before and after deducting non-recurring gains and losses.